Selinexor Treatment of Advanced Relapsed/Refractory Squamous Cell Carcinomas
Status:
Terminated
Trial end date:
2015-12-10
Target enrollment:
Participant gender:
Summary
Open-label, multi-center, single-arm, Phase 2 study of oral selinexor in patients with SCC of
the head and neck (HN-SCC; Cohort 1), lung (L-SCC; Cohort 2), or esophagus (E-SCC; Cohort 3)
who have relapsed or have metastasis following chemotherapy.